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Recent advances in multi-disciplinary research have resulted in the emergence of an 
increasing number of promising therapeutic strategies against cancer. However, the 
intravenous administration of these drugs is often limited by their inability to 
specifically reach the tumors, thus resulting in damaging secondary effects on 
healthy tissues. In order to remediate to this problem, a wide range of delivery 
systems have been investigated, aiming to specifically target the cancer cells and 
deliver their cargo to the pathological site. Among them, transferrin-bearing 
dendrimers are emerging as highly promising non-viral vectors for efficiently 
delivering drugs and nucleic acids to the cancer cells. The focus of this editorial is to 
provide an update on the therapeutic advances being made so far when using these 
targeted delivery systems.  
 
Why using transferrin for targeting cancer cells? 
Transferrin, a member of the family of iron-binding glycoproteins, has for main role to 
bind and distribute iron in the body to various target tissues overexpressing 
transferrin receptors (TfR) 1 and 2 [1-2]. Despite being expressed at low levels on 
most normal tissues, TfR1 is overexpressed on highly proliferative cells such as 
cancer cells (at levels higher than 100-fold compared to normal cells) [3-5]. 
Transferrin can also bind to TfR2, whose Į-transcript product is mainly expressed on 
hepatocytes, but with 25-fold less affinity than for TfR1 [6]. In addition, the level of 
expression of TfR1 on tumors is correlated with cancer progression and tumor stage, 
making it a particularly promising target for the delivery of anti-cancer therapeutics to 
tumors [3-5].  
 
 5 
Why using dendrimers as delivery systems for cancer therapy?  
Dendrimers present unique advantages that make them highly promising for the 
delivery of drugs and nucleic acids to cancer cells. These highly branched polymers 
are composed of multiple monomers emerging radially from a central core similarly to 
a tree (³'HQGURQ´ in Greek) [7-11]. Thanks to their structure and spherical shape, 
they present a large number of surface functionalities that can be utilized for 
conjugating targeting ligands or drugs, as well as complexing nucleic acids. Their 
radial ramification of dendrons also delimitates internal cavities that have been used 
for the entrapment of anti-cancer drugs [7-11]. These features made them unique, 
extremely attractive polymers.  
 
Recent use of transferrin-bearing dendrimers for cancer therapy 
Despite their promising characteristics, transferrin-bearing dendrimers or TfR-
targeting dendrimers have not been widely used so far. In a study by Han and 
colleagues, a PEGylated generation 5- poly (amido amine) (PAMAM) dendrimer was 
conjugated to the peptide HAIYPRH (T7), which is transferrin receptor-specific [12].  
This dendrimer was able to co-deliver the anti-cancer drug doxorubicin (entrapped 
within its internal cavities) and a therapeutic plasmid encoding human tumor necrosis 
factor-related apoptosis±inducing ligand (TRAIL) (complexed to its surface by 
electrostatic interactions) (average size of the dendriplex: 200 nm). The presence of 
T7 peptide on the surface of the dendrimer enhanced the cellular uptake by the 
human liver cancer Bel-7402 cells overexpressing Tf receptors, compared to what 
observed with the non-targeted dendrimer. In vivo, the following intravenous 
administration of this dendriplex led to a synergy between the two therapeutic entities 
carried by the same dendrimer, resulting in the inhibition of 77% tumor growth on 
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mice bearing subcutaneous Bel-7402 human hepatoma. This impressive therapeutic 
effect was much higher than that observed with the drug only or the non-targeted 
dendrimer [12].  
Another PEGylated PAMAM dendrimer has been studied for the treatment of C6 
glioma. The targeting strategy in this study was different compared to the previous 
study. In this case, the dual targeting Tf- wheat germ agglutinin (WGA) was intended 
to target the TfR1 present on the blood-brain barrier, not on the tumor: TfR1 is 
expressed at low levels in most normal tissues, but is highly expressed on the 
vascular endothelium of the brain capillaries among normal tissues [13]. As a result, 
TfR1-targeting on mice without peripheral tumors would therefore reach the brain, 
whereas a similar targeting on mice bearing peripheral tumors would mainly reach 
the tumors. Tf- and WGA- bearing PEGylated generation 4-PAMAM dendrimer 
loaded with doxorubicin (average size of the drug-loaded dendrimer: 199 nm) was 
able to decrease the viability of  C6 glioma cells in a brain microvascular endothelial 
cells (BMVEC)/C6 glioma co-culture model. The viability of C6 glioma cells was 14.5 
% in comparison with 21.3 % for PAMAM-PEG-Tf-DOX, 23.7 % for PAMAM-PEG-
WGA-DOX and 22.4 % for free DOX [14].  
A pH-sensitive dual-targeting PEGylated generation 4-PAMAM dendrimer was also 
synthesized by conjugating Tf on the surface of the dendrimer and entrapping 
tamoxifen and doxorubicin (average size of the drug-loaded dendrimer: 117 nm) [15]. 
The resulting dendrimer exhibited high BBB transport ability across an in vitro BBB 
model and displayed an accumulation of doxorubicin in avascular C6 glioma 
spheroids. 
We recently used another dendrimer, generation-3 diaminobutyric polypropylenimine 
(DAB) as an alternative of PAMAM for cancer therapy. As demonstrated by Kabanov 
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and colleagues [16], one of the advantages of this dendrimer is that it binds to DNA 
via electrostatic interactions involving only the peripheral amine groups, leaving the 
WHUWLDU\ DPLQH JURXSV LQ WKH GHQGULPHU IUHH WR DFW DV D ³SURWRQ VSRQJH´ LQ WKH
endosome. We recently demonstrated that Tf-bearing DAB dendriplex (average size: 
287 nm) resulted in gene expression mainly in the tumors after intravenous 
administration [17]. Consequently, the intravenous administration of this dendrimer 
FRPSOH[HGWRDWKHUDSHXWLF'1$HQFRGLQJWXPRUQHFURVLVIDFWRU71)ĮUHVXOWHGLQ 
the disappearance of 90% of A431 human epidermoid carcinoma  tumors, compared 
to the 40% complete tumor regression observed with the non-targeted dendriplex 
[17].  
It was less efficacious on prostate cancer cells, resulting in tumor suppression for 
60% of PC-3 and 50% of DU145 prostate tumors [18]. In a parallel study, we wanted 
to evaluate the therapeutic potential of a plasmid DNA encoding p73, a member of 
the p53 family of transcription factors, following complexation to DAB-Tf. We 
demonstrated that, indeed, systemically administered p73-encoding DAB dendriplex 
resulted in a prolonged inhibition of tumor growth and tumor suppression for 10% of 
A431 and B16-F10 tumors in mice [19]. Crucially, the treatments with the various 
tested dendriplexes were well tolerated by the animals.  
 
Future perspective 
TfR±targeting dendrimers have demonstrated to be efficacious delivery systems for 
therapeutic genes and drugs to cancer cells and have already led to significant 
improvements in the systemic delivery of therapeutic entities to their site of action. 
Still, the question of absolute targeting remains unanswered (and may still be so for a 
long time?). So far, we do not have 100% of drugs or genes delivered exclusively to 
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the tumors, using Tf or any other targeting ligand. Various strategies are currently 
investigated to improve the level of tumor targeting, with more or less success. For 
example, we recently investigated if the replacement of Tf by Lactoferrin (Lf), an iron-
binding member of the Tf family which has intrinsic anti-cancer properties [20], on the 
surface of DAB, would lead to improved tumor targeting and improved therapeutic 
efficacy. The conjugation of Lf to DAB dendrimer increased gene expression in the 
tumor while decreasing the non-specific gene expression in the liver, but with tumor 
targeting effects that were not improved compared to that obtained with DAB-Tf [21]. 
The intravenous administration of Lf-EHDULQJ '$% GHQGULSOH[HV HQFRGLQJ 71)Į 
(average size: 260 nm) led to suppression of 60% of A431 tumors and up to 50% of 
B16-F10 tumors [21].  
Other studies have investigated the use of anti-TfR monoclonal antibodies for 
enhancing tumor targeting. However, unlike Tf, these antibodies do not appear to 
have more affinity for tumor-overexpressed TfR1 than for non-specific TfR2 [22].  
The use of dual targeting as another strategy to increase tumor targeting of Tf-
bearing dendrimers appears to be promising and is currently under investigation. As 
described above, this strategy has already proven its efficacy for its targeting of the 
blood-brain barrier and should hopefully demonstrate the same improvement on 
cancer cells.  
'HVSLWHWKHQHHGRI³ILQHWXQLQJ´FDQFHUWDUJHWLQJWKHencouraging advances related 
above demonstrate that the targeting of Tf receptor still remains a huge potential for 
the development of more specific and safer gene and drug-based therapeutics. 
Clinical trials using dendrimers in cancer therapy are still pending, but dendrimers 
have already been successfully introduced in the clinic as anti-viral agents. It is 
hoped that continuous research in this area would enable the V\QWKHVLV RI ³QH[W
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JHQHUDWLRQ´7I-bearing dendrimers-based nanomedicines, expected to provide many 
exciting therapeutic opportunities and to pave the way for better treatment options 
against cancer.  
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